bluebird bio, Inc.
bluebird bio, Inc. (BLUE): 5 pipeline candidates · ~8 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.1 months
D/E -6.11 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for bluebird bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$92.3M
Quarterly Burn
$43.4M
Runway
8.1 mo
Revenue
$38.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in bluebird bio, Inc.'s pipeline?
bluebird bio, Inc. (BLUE) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is bluebird bio, Inc.'s lead drug candidate?
bluebird bio, Inc.'s most advanced tracked candidate is axumin (Approved).
What is bluebird bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, bluebird bio, Inc. has approximately 8.1 months of cash runway.
Who is the CEO of bluebird bio, Inc.?
Grand Un is the chief executive officer of bluebird bio, Inc. (BLUE).
Get the full picture on bluebird bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.